LATEST MULTIPLE MYELOMA CONTENT

CARTITUDE-4 Data, IMWG Guideline Make the Case for Second-Line CAR T in Myeloma

Examining the Strongest Options for Heavily Pretreated Myeloma After Bispecific Therapy

New Considerations Arise in Sequencing After Second Relapse in Multiple Myeloma

Defining Key Questions on Adopting Quadruplet Regimens in NDMM

Tec/Dara Offers a Path Forward in Relapsed Myeloma When CAR T Is Not an Option

Early CAR T Brings Questions of Preferred Bridging in Multiple Myeloma

Reflecting on CAR T for First Relapse in Multiple Myeloma

Using Novel Mechanisms of Action as Myeloma CAR T Bridging Therapy
CASE-BASED ROUNDTABLES
Advertisement
Advertisement

